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Grand Rounds: Department of Internal Medicine 
Myasthenia Gravis* 
Stanton B. Elias, MD^ 
During the past two decades the concept of myasthenia gravis has changed radically. At one time myasthenia gravis was 
defined as a neuromuscular disease affecting voluntary skeletal 
muscles and producing weakness and fatigability. Myasthenia 
gravis was subsequently classified as an autoimmune disease in 
which antibodies directed against the acetylcholine receptor 
produce neuromuscular failure, weakness, and fatigability. 
Much of the pathophysiology of this disease has evolved in the 
last 20 years, and myasthenia gravis can now be considered as a 
prototype in terms of understanding the pathogenesis of many 
other autoimmune diseases. 
Pathophysiology 
In the 1960s there was great controversy about whether my-
asthenia gravis was a presynaptic disease, something that 
evolved from an abnormality in the packaging or manufacture of 
acetylcholine in the presynaptic terminal in the neuromuscular 
junction, or a postsynaptic disease, an abnormality in the acetyl-
choline receptor or in the transduction of the signal in the muscle 
membrane to produce muscle contraction. In the mid 1960s, 
Elmqvist and Lambert (1) found that the miniature end plate po-
tential—the small depolarization of the postsynaptic membrane 
that came from the spontaneous release of a single quantum of 
acetylcholine—was reduced in amplitude to about 10% to 30% 
of normal. From another set of experiments, which was limited 
by the technology at that time, they thought that the postsynaptic 
membrane had a normal sensitivity and therefore suggested that 
myasthenia gravis was a presynaptic abnormality that resulted 
from small packets of acetylcholine being released (1). This was 
the predominant belief throughout the 1960s. However, in 1971, 
Engel and Santa's (2) morphometric electron microscopic stud-
ies of the postsynaptic membrane produced the following 
results: 
1. The projections of the postsynaptic membrane where the 
acetylcholine receptors reside, the postsynaptic vi l l i , were 
markedly altered and, in fact, destroyed. 
2. The presynaptic structures, the nerve terminals, were nor-
mal. The size of the presynaptic vesicles was normal, and the 
presynapdc structures were not significandy altered. 
3. The synaptic cleft was widened and contained debris that 
appeared to be the terminals of the postsynaptic membrane. 
In addition to the morphologic suggestion that a postsynaptic, 
rather than presynaptic, abnormality was responsible for my-
asthenia gravis, biochemical studies in the 1970s helped to lo-
calize and quantify the acetylcholine receptors. By studying the 
mechanism of action of poisonous snake venom, Chang and Lee 
found that alpha-bungarotoxin binds specifically and irreversi-
bly to the acetylcholine receptor (3). This enabled the produc-
tion of a labeled ligand for the acetylcholine receptor that bound 
specifically and irreversibly, thereby allowing the identification 
of acetylcholine receptors in normal and in myasthenic muscle. 
Fambrough et al (4) documented that the acetylcholine receptors 
in the postsynapdc membrane of myasthenic muscles were re-
duced to 10% to 30% of normal. 
As technology for electrophysiology improved, Albuquerque 
et al (5) were able to apply acetylcholine directly on to the 
postsynaptic membrane by using Nomarsky Opdcs, which doc-
umented that the decrease in sensitivity was consistent with the 
decrease in the number of acetylcholine receptors. 
Thus, while it was firmly established by the mid 1970s that 
myasthenia gravis was a postsynaptic disease of acetylcholine 
receptors, the cause of this dysfunction was still unknown. 
Much of the evidence pointed toward myasthenia gravis being an 
autoimmune disease. This was first suggested in the late 1950s 
when an increased prevalence of other autoimmune diseases in 
myasthenic patients was noted. More evidence resulted from the 
development of another cholinergic ligand from poisonous 
snake venom. Like the alpha-bungarotoxin, alpha cobra toxin is 
also a very specific ligand that binds to acetylcholine receptors. 
However, because it is a reversible binding it was possible to at-
tach alpha cobra toxin to a column and to purify acetylcholine 
receptors. Since acetylcholine receptors are found in high con-
centrations in the organs of the electric ray and the electric eel, 
it was therefore possible to use these electric organ tissues to 
purify large amounts of acetylcholine receptors. 
Patrick and Lindstrom (6), who conducted these experiments, 
decided it would be interesting to study the acetylcholine recep-
tor using a very specific antibody. Therefore, they attempted to 
immunize rabbits to the acetylcholine receptor, but the rabbits 
died consistently. From consultations with a neurologist, they 
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found that myasthenia gravis was the cause of the weakness and 
death ofthese rabbits. Thus, experimental autoimmune my-
asthenia gravis was discovered. Investigators found that in its 
chronic phase experimental autoimmune myasthenia gravis is 
morphologically, biochemically, and electrophysiologically 
identical to the human form of the disease. The only difference 
was in the acute phase of the experimental disease in which a 
cellular infiltration of the end plate occurred. To our knowledge, 
this does not occur in human myasthenia gravis. 
Following these experiments, it was thought that myasthenia 
gravis also might have an antibody to the acetylcholine receptor. 
A variety of techniques were used to detect and quantify the anti-
bodies that bind to the acetylcholine receptor in the serum of pa-
dents with myasthenia gravis. By using specific ligands, it was 
possible to localize these antibodies to the end plate. 
Finally, it became possible to transfer myasthenia gravis from 
man to mouse by using purified antibodies and injecting them 
chronically into mice. This experiment suggested that my-
asthenia gravis could be caused by a circuladng agent. Indeed, 
about 15% of infants of myasthenic mothers are clinically weak 
at birth or immediately following birth. These infants have tran-
sient neonatal myasthenia gravis which clears within three to six 
weeks and is due to a circulating antibody. 
With the discovery of antibodies against the acetylcholine re-
ceptor, it was believed that myasthenia gravis could be under-
stood quite easily. It was inidally thought that these antibodies 
would go into the neuromuscular junction, block the action of 
acetylcholine, and produce a neuromuscular blockade. How-
ever, several factors suggested that the answer was not that sim-
ple. First, there is a poor correlation between the state of the 
clinical disease and the titer of acetylcholine receptor antibodies 
in the serum of these patients. Second, if serum andbodies from 
a myasthenic padent are applied to a neuromuscular preparation 
in vitro, no blockade is produced. Investigators thus presumed 
that the antibody was involved in a more complicated process. It 
was later documented that the andbodies that bound to the 
acetylcholine receptor in the postsynaptic membrane acdvated 
the lydc phase series of complement so that there was comple-
ment-mediated lysis of the postsynapdc membrane with actual 
destrucdon of the tips of the membrane containing the acetyl-
choline receptors. A second group of experiments measuring the 
turnover of acetylcholine receptors in muscle culture found that 
acetylcholine receptor antibodies accelerated the degradation of 
these receptors to a level two to four times as fast as expected 
with normal serum. Therefore, at least two mechanisms were 
known to produce the loss of acetylcholine receptors in the 
postsynaptic membrane: the complement-mediated lysis, and 
the receptor modulation by the antibody. 
The uldmate acdon of the acetylcholine receptor andbodies is 
sdll not understood. The presence of the antibody is not suffi-
cient to explain or produce the disease. Patients who are in re-
mission from the disease may have a very significant titer of the 
antibody and yet have no myasthenia gravis. One possible 
explanation is that acetylcholine receptors differ between one 
patient and another, and that difference is what mediates the vari-
ation in disease. 
There are several binding characterisdcs of acetylcholine re-
ceptors. These receptors can be blocking or nonblocking, ie. 
some will block the binding of alpha-bungarotoxin and some 
will not. There are also two types of acetylcholine receptors: 1) 
those which are found in normal innervated muscles, limited to 
the neuromuscular junction; and 2) those which occur after de-
nervation and spread across the muscle membrane. Studies have 
found that myasthenic patients have antibodies with several dif-
ferent binding characterisdcs. 
The acetylcholine receptor consists of an alpha subunit that 
contains the acetylcholine binding site. Two of these alpha sub-
units, as well as three other subunits (beta, gamma, and delta), 
are within the acetylcholine receptor. These receptor subunits 
can be purified and used to produce the experimental autoim-
mune myasthenia gravis. The alpha subunit is the most effective 
subunit in producing weakness in animals; however, the native 
receptor is always more effective in producing the disease than 
any of the subunits. Within a particular myasthenic patient, 
most of the antibodies are directed toward an epitope referred to 
as the main immunogenic region which resides on the alpha sub-
unit. While some antibodies are directed toward the other sub-
units, they do not appear to be important in determining the 
severity of the disease. Severity of disease is determined by 
something other than the type or titer of andbody that is found 
within a myasthenic patient. 
Transient neonatal myasthenia gravis can help to explain the 
significance of the different types of antibodies. While transient 
weakness occurs in about 15% of infants of myasthenic mothers, 
about 60% of these infants have antibodies to the acetylcholine 
receptor Neither the degree to which the mother is weak nor the 
level of her antibody titer determines whether or not transient 
weakness occurs. One of our cases involved a mother who had a 
significant titer of acetylcholine receptor antibodies but was in 
total clinical remission and off all medication during the last half 
of her pregnancy. Her infant, who had a slighdy lower dter of 
antibody, was significantly weak and required treatment. Later, 
as the acetylcholine receptor was metabolized, the infant im-
proved. This case suggests that the same antibody can have dif-
ferent effects on different individuals. Even though the mother 
was in remission, some of her antibodies circulated to the fetus, 
producing weakness in the infant after birth. Thus, idendcal 
antibodies can cause significant differences in the severity of 
weakness in two individuals. The biologically acdve antibody 
was present in the mother yet did not produce weakness. There-
fore, host factors may be important in determining the clinical 
state in myasthenic patients. Some ofthese host factors may be a 
difference in the biochemistry of the motor end plate, ie, infants 
have different types of motor end plates than adults. Other pos-
sibilides include either the hormonal background in which the 
antibodies are acdng or other blocking factors. Studies have 
shown that a significant percentage of myasthenic patients have 
and-idiotypic antibodies circuladng against the acetylcholine 
receptor andbody, and possibly these and-idiotypic antibodies 
mediate a much more benign form of the disease in some 
patients with myasthenia gravis. 
Incidence 
In their 1971 study of over 1,200 patients with myasthenia 
gravis, Osserman and Genkins (7) observed that the distribudon 
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of the incidence of myasthenia gravis is essendally a bimodal 
curve, with a peak incidence among young women and a second 
peak occurring among the elderly. In the latter group the sex dis-
tribution is essentially equal, although the incidence among el-
derly men tends to be somewhat higher We have also noted the 
same bimodal curve, although in our series the age distribudon 
increased by ten years, which may reflect that many of our pa-
tients began treatment at Henry Ford Hospital in the middle 
rather than in earlier stages of the disease. We also observed that 
myasthenia gravis affects two women per one man. 
Symptomatology 
One of the hallmarks of this disease, compared to other neu-
romuscular diseases, is that ocular muscles are charac-
teristically involved. Alternating ptosis between the right and 
the left eye is almost pathognomonic of myasthenia gravis. 
Bulbar musculature is also affected. Symptoms may include 
hoarseness, difficulty with chewing, swallowing, and holding 
up the head, and respiratory crisis. Because patients are at high 
risk for respiratory failure, being aware of the patient's respira-
tory status is the key to management of this disease. At one dme 
myasthenia gravis had a mortality rate of 20% to 30%, mostly 
due to respiratory failure and concurrent infection. A large 
number of patients may have generalized skeletal muscle weak-
ness as well, and this may occur at the onset or later on in the 
course of the disease. 
Classification 
Myasthenia gravis has been classified in several different 
ways. Osserman and Genkins" (7) classification of the disease is 
commonly used. For adults, group 1 includes patients who have 
weakness localized to the eye muscles, such as ptosis and dip-
lopia. This group represents approximately 20% of all patients 
with myasthenia gravis. If the disease has not progressed beyond 
involvement ofthe eye muscles within two years after onset, it is 
unlikely that the disease will progress further. Studies have 
shown that ofthe more than 90% of patients presenting with 
ocular findings, those who will progress to generalized my-
asthenia will do so by the end of two years. Group 2 includes 
patients with generalized myasthenia; mild 2A and 2B represent 
moderate severity with more bulbar symptoms. Group 3 in-
cludes those patients with a rapidly progressive course, usually 
resulting in respiratory failure within the first six months to one 
year after onset of the disease. Many of these padents have a 
thymoma. Group 4 represents a late progressive form of my-
asthenia gravis in which the severity of symptoms gradually in-
creases over a period of years. Typically, the greatest degree of 
severity occurs within the first three years after onset. 
A different type of classification, suggested recently by 
Compston et al (8), is based on the genetics and immunology of 
myasthenia gravis. Approximately 10% to 15% of myasthenic 
patients have a tumor of the thymus. In group 1 of this classifica-
tion, no sex prevalence, HLA predominance, or characteristic 
HLA typing is seen. Groups 2 and 3 include patients without a 
thymoma. These patients appear to have a genetic predisposi-
don toward acquiring myasthenia gravis. Those with onset be-
fore age 40 are predominately females. Patients in this age group 
have a 10% incidence of associated autoimmune diseases and 
share certain HLA antigens. Those with onset after age 40 are 
predominately males. The HLA types noted in this group are 
different from those seen in the younger age group, and these 
patients have a greater incidence of other associated autoim-
mune disea.ses. 
In Osserman and Genkins' study (7), the more common asso-
ciated autoimmune diseases included thyroid dysfunction (10% 
to 15%), diabetes mellitus (6%), and rheumatoid arthritis (3%). 
A smaller number of patients developed polymyosids, systemic 
lupus, vitiligo, pernicious anemia, and sarcoidosis. A variety of 
other autoimmune endocrine disorders have also been associ-
ated with myasthenia gravis. 
Diagnosis 
Myasthenia gravis is diagnosed in several steps. While associ-
ated autoimmune diseases should be considered in the initial 
workup, the medical history and physical examination is the first 
and most important step in diagnosing the disease. The second 
step involves repetitive nerve stimulation or single fiber elec-
tromyogram (EMG) tests to document the neuromuscular 
blockade. Repetitive stimulation, or the Jolly test, is carried out 
by stimulating the nerve at 3 cycles/sec and recording the resul-
tant compound action potential from muscle. Myasthenia gravis 
would be diagnosed by seeing the typical decremental response. 
Single fiber EMG is a more sophisticated means of determining 
neuromuscular blockade and transmission failure. With proper 
testing of appropriate muscles, results should be positive in 
about 95% of patients with myasthenia gravis. 
The anti-acetylcholine receptor antibody, the key figure in the 
autoimmune aspect of this disorder, is present in about 90% of 
patients with generalized myasthenia gravis and in about 50% of 
patients with the disease limited to the eye muscles. Antistriated 
muscle antibodies, discovered in the early 1960s, were the first 
clue to the autoimmunity in myasthenia gravis. These antibodies 
will stain muscle striations, such as the A band, the I band, and 
the Z band. Interestingly, while these andbodies are present in 
30% of patients with myasthenia gravis, they apparently do not 
participate in the pathogenesis of the disease. Of patients with 
myasthenia gravis who have a thymoma, 95% will also have the 
antistriated muscle andbodies, although only 50% of patients 
with antistriated muscle antibodies will have a thymoma. Thus, 
the presence of antistriated muscle antibodies is a good marker 
for the possible presence of a thymoma. For this reason, chest 
x-ray and chest computed tomography are routine tests in the 
evaluation of the patient with myasthenia gravis. While 10% 
to 15% of patients will have a frank thymoma, another 70% of 
patients will have an enlargement of the thymus, or thymic 
hyperplasia. 
Other diagnostic tests for myasthenia gravis include tests for 
collagen vascular disease, thyroid function tests, and the ten-
silon test. The tensilon test involves injecdon of a short-acting 
anticholinesterase which will improve neuromuscular transmis-
sion for about three to five minutes and thus aid in the diagnosis 
of myasthenia gravis. Although the older literature reports that 
the tensilon test is the key to diagnosing myasthenia gravis, this 
test presents two problems: I) a large number of padents will 
have a false-positive tensilon test because of the severe cho-
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linergic side effects of this drug, and 2) tensilon can cause respi-
ratory failure in patients with compromised respiratory func-
tion. This can be a serious problem since some patients with 
compromised respiratory function may escape detection at the 
inidal examination. 
Henry Ford Hospital Experience 
Approximately 147 patients with myasthenia gravis were seen 
at Henry Ford Hospital between 1983 and 1987, although that 
number has risen to over 180 patients to date. This total repre-
sents perhaps 20% of all myasthenic patients in Michigan. 
Clinic visits range between between 450 and 500 per year, which 
indicates that many padents with this disease need to be seen 
frequently. Whereas probably 50% of the padents are seen only 
once or twice a year because they are in stable condition, the 
others must be seen once a month or more often. We have ap-
proximately 25 hospital admissions per year, which includes 
one or two patients with a respiratory crisis necessitating a pro-
longed hospital stay. 
Of the 147 patients seen between 1983 and 1987, 44 padents 
received thymectomies. A similar number were demonstrated to 
have associated autoimmune diseases. Thyroid disease was 
more prevalent in our group than in Osserman and Genkins' 
group, which is likely not a significant difference. Other fre-
quendy seen associated diseases included diabetes mellitus and 
vidligo. A few padents had pernicious anemia, rheumatoid ar-
thritis, and sarcoidosis. One patient had immune throm-
bocytopenic purpura, one had scleroderma, and one had 
polymyositis. 
Treatment 
Several forms of treatment are used for myasthenia gravis. 
The andcholinesterases, a purely symptomadc form of treat-
ment, essentially augment the signal from nerve to muscle, stop-
ping the breakdown of acetylcholine. Pyridosdgmine bromide 
is the most commonly used anticholinesterase. 
Thymectomy is another form of treatment. Abnormality of 
the thymus was one of the early clues to the autoimmunity of 
myasthenia gravis, and removal or irradiation of the thymus was 
shown to ameliorate the course of the disease. Thus, thymec-
tomy is recommended for virtually all patients with severe or 
moderate myasthenia gravis. A recent study reported that thy-
mectomy in patients without a thymoma increased the remission 
rate after several years to between 30% and 50% (9). 
Corticosteroids have an unusual affect on myasthenic pa-
dents. When corticosteroids are given in high doses from the 
onset, within three days to two weeks about 30% to 50% of pa-
tients get weaker and 10% of these patients may develop respira-
tory crisis. However, most of these patients will improve after 
three to six weeks of corticosteroid therapy, and as many as 50% 
will go into remission. Unfortunately, corticosteroid therapy is 
imperfect. It is difficult to discondnue steroids in these padents 
after time. They become steroid-dependent, which leads to fur-
ther complications. 
Other immunosuppressive agents, pardcularly azathioprine, 
have been used to treat myasthenia gravis, but this has been 
much more popular in Europe than in the United States. While 
30% to 50% of patients may go into remission with azathio-
prine, it may take up to one year for maximum effect to occur 
and patients can become dependent on the drug. Studies have 
shown that discontinuation of azathioprine will often result in a 
recurrence of the disease within six months. 
We follow the principle that patients with ocular or very mild 
myasthenia gravis may be treated symptomadcally, but an ag-
gressive approach to the immune cause ofthe disease is impor-
tant for patients with more severe myasthenia gravis. As men-
tioned previously, the key to management of myasthenia gravis 
is being aware of whether or not these patients have any respira-
tory compromise. Respiratory compromise may not be obvious 
when examining skeletal muscle involvement since respiratory 
muscles can be involved out of proportion to any other skeletal 
muscle involvement. However, one waming signal is when pa-
tients develop other bulbar symptoms such as difficulty with 
chewing or swallowing. 
For padents with mild myasthenia gravis, treatment includes 
anticholinesterase therapy; thymectomy is also recommended 
only for those with generalized myasthenia gravis. Patients with 
the disease limited to the ocular muscles can be treated with and-
cholinesterases followed by small doses of steroids. 
For those with moderate myasthenia gravis, thymectomy is 
recommended, preferably early on in the course of the disease. 
Andcholinesterase medications can be used as an adjunct, and 
steroids can be used if these padents are functionally unable to 
carry out their normal daily activities. 
For padents with severe myasthenia gravis, the key is being 
aware of their respiratory compromise and protecting them 
against respiratory failure. These patients should be monitored 
in the intensive care unit. Respiratory parameters should be 
measured frequently in other patients who may be developing 
respiratory insufficiency. Plasmapheresis may produce im-
provement in patients with severe myasthenia gravis; however, 
improvement may not occur for seven days to two weeks be-
cause the neuromuscular blockade stems from a decreased 
number of acetylcholine receptors and the end plate must be al-
lowed to heal. Steroids, usually begun ih high doses, might also 
be helpful for patients with severe myasthenia gravis. Anti-
cholinesterase may not be u.seful for patients in respiratory crisis 
since it may cause excessive bronchial secretions and make 
treatment more difficult for these intubated padents. Thymec-
tomy is not recommended until after these padents are in stable 
condition. Azathioprine may also be considered as treatment for 
the long term. 
Why do some patients who have had stable myasthenia gravis 
for a long period of time suddenly deteriorate? We have devel-
oped five categories to classify these types of patients. The first 
category includes patients who simply have a worsening of their 
myasthenia gravis. The second group includes patients who 
have therapeutic complications. For example, patients with ex-
cess cholinergic effects from the andcholinesterases develop a 
cholinergic blockade, which is manifested by other side effects 
such as an excess in salivation and sweating, tearing, diarrhea, 
and abdominal cramps. Also, patients may have a steroid myop-
athy or steroid-induced hypokalemia that produces excessive 
weakness. The third group includes patients who become worse 
because of changes in related diseases. Forexample, patients 
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who develop thyroid dysfunction, such as hyperthyroidism or 
hypothyroidism, may have a worsening of myasthenia gravis. 
The fourth group includes patients who become worse becau.se 
of unrelated diseases. Any other intercurrent infecdon, pardcu-
larly upper respiratory infections or pneumonia or even dental 
abscesses, can lead to respiratory crisis. In fact, any unrelated 
disease, such as cancer or stroke, can cause myasthenia gravis to 
worsen. The fifth group includes patients who become worse 
because of side effects of medication. While aminoglycoside an-
tibiotics, which are neuromuscular blockers, do not present 
problems to the nonmyasthenic patient who has ten dmes more 
acetylcholine receptors than are needed, for the myasthenic pa-
dent who has only 10% to 20% of the normal number of acetyl-
choline receptors, a blockade of 30% or 40% of those receptors 
may produce a significant effect. Other medications that can 
produce weakness in myasthenic padents include beta blockers 
and membrane stabilizers. 
Potential new treatments for myasthenia gravis include 
cyclosporine, specific plasmapheresis, and specific immu-
notherapy. Cyclosporine has been tried, but its effects are not 
sufficient to use as the sole agent for treatment of myasthenia 
gravis. A clinical trial will be undertaken in the near future to 
investigate the use of cyclosporine as a replacement for steroids. 
Plasmapheresis with specific filters may also be used in the fu-
ture. In this procedure, the acetylcholine receptors are bound to 
the filters so that only the antibodies against the acetylcholine 
receptors will be removed, which obviates the need for plasma 
replacement. Specific immunotherapy to induce competing 
andbodies or and-idiotypic antibodies has also been suggested. 
Immunizadon of animals with denatured acetylcholine recep-
tors has already been shown to ameliorate the course of experi-
mental autoimmune myasthenia gravis. 
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